Alveron Pharma

Based in Nijmegen, The Netherlands, Alveron Pharma specializes in developing innovative therapies for neurological emergencies, focusing on rapid treatment solutions for acute stroke cases. Alveron Pharma, founded in 2019 in Nijmegen, Netherlands, develops therapies targeting acute neurological conditions. The company's co-founders are Alex Zwiers and Stephan Peters, while Ben Nichols serves as CEO. Alveron has completed a total of 4 deals, with its most recent funding round occurring on December 6, 2024, during which it raised EUR 5 million in SEED funding led by Broadview Ventures and included participation from other investors like Thuja Capital and Waterman Ventures.

The total funds raised to date amount to EUR 5 million. Alveron Pharma's core product offering is OKL-1111, a novel therapy designed for the rapid treatment of haemorrhagic stroke, particularly intracranial haemorrhage (ICH). This drug acts as a universal reversal agent that does not require prior identification of the anticoagulant used by the patient, allowing for immediate treatment in critical situations. Targeted primarily at hospitals and emergency care facilities, Alveron aims to market OKL-1111 in Europe and North America to address the high incidence of stroke-related complications.

Alveron Pharma's revenue model focuses on direct sales of OKL-1111 to healthcare institutions and providers. The company plans to establish partnerships with hospitals and emergency departments to facilitate swift distribution and implementation of the therapy. Pricing will be negotiated on a case-by-case basis, particularly with facilities prioritizing rapid access to life-saving treatments, thereby positioning Alveron as a critical partner in the acute neurological therapy market. Following the recent SEED funding of EUR 5 million, Alveron Pharma plans to advance the development of OKL-1111 to support further clinical studies to prove safety and efficacy.

The company is also exploring expansion into additional European markets and North America. The funding will specifically help prepare OKL-1111 for clinical trials aimed at demonstrating its effectiveness in treating ICH, with an emphasis on improving patient outcomes through timely interventions.